73852 Federal Register / Vol. 72, No. 248 / Friday, December 28, 2007 / Notices 

and management of information 

supporting the process for the review of 

human drug applications throughout the 

product life cycle. As part of this 

process, FDA will develop and 

periodically update a 5-year IT plan and 

will solicit and consider comments from 

the public on the draft IT plan. At the 

end of the comment period, FDA will 

review the comments, update the IT 

plan, and publish the final version no 

later than May 30, 2008. 

II. Comments 

Interested persons may submit to the 

Division of Dockets Management (see 

ADDRESSES) written or electronic 

comments regarding this document. 

Submit a single copy of electronic 

comments or two paper copies of any 

mailed comments, except that 

individuals may submit one paper copy. 

Comments are to be identified with the 

docket number found in brackets in the 

heading of this document. Received 

comments may be seen in the Division 

of Dockets Management between 9 a.m. 

and 4 p.m., Monday through Friday. 

Please note that in January 2008, the 

FDA Web site is expected to transition 

to the Federal Dockets Management 

System (FDMS). FDMS is a 

Government-wide, electronic docket 

management system. After the transition 

date, electronic submissions will be 

accepted by FDA through the FDMS 

only. When the exact date of the 

transition to FDMS is known, FDA will 

publish a Federal Register notice 

announcing that date. 

III. Electronic Access 

Persons with access to the Internet 

may obtain the document at http:// 

www.fda.gov/ohrms/dockets/ 

default.htm. 

Dated: December 20, 2007. 

Jeffrey Shuren, 

Assistant Commissioner for Policy. 

[FR Doc. E7–25310 Filed 12–27–07; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Clinical Center; Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the NIH 

Advisory Board for Clinical Research. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. The meeting 

will be closed to the public in 

accordance with the provisions set forth 

in section 552b(c)(6), Title 5 U.S.C., as 

amended to discuss personnel matters, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: NIH Advisory Board 

for Clinical Research 

Date: January 28, 2008. 

Open: 10 a.m. to 1:15 p.m. 

Agenda: To review the 2008 Clinical 

Center Operating Plan and provide updates 

on selected organizational initiatives. 

Place: National Institutes of Health, 

Building 10, 10 Center Drive, CRC Medical 

Board Room 4–2551, Bethesda, MD 20892. 

Closed: 1:15 p.m. to 2 p.m. 

Agenda: To review and evaluate personnel 

matters. 

Place: National Institutes of Health, 

Building 10, 10 Center Drive, CRC Medical 

Board Room 4–2551, Bethesda, MD 20892. 

Contact Person: Maureen E Gormley, 

Executive Secretary, Mark O. Hatfield 

Clinical Research Center, National Institutes 

of Health, Building 10, Room 6–2551, 

Bethesda, MD 20892, 301–496–2897. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Dated: December 18, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–6208 Filed 12–27–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the meeting of the 

President’s Cancer Panel. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. The meeting 

will be closed to the public in 

accordance with the provisions set forth 

in section 552(c)(9)(B), Title 5 U.S.C., as 

amended, because the premature 

disclosure of information and the 

discussions would likely to significantly 

frustrate implementation of 

recommendations. 

Name of Committee: President’s Cancer 

Panel. 

Date: January 28, 2008. 

Open: January 28, 2008, 7:30 a.m.–3:30 

p.m. 

Agenda: Strategies for Maximizing the 

Nation’s Investment in Cancer. 

Place: Chateau Sonesta Hotel, 800 Iberville 

St., New Orleans, LA 70112. 

Closed: January 28, 2008, 4 p.m.–6 p.m. 

Agenda: Strategies for Maximizing the 

Nation’s Investment in Cancer and discuss 

potential topics for the 2008/2009 series. 

Place: Chateau Sonesta Hotel, 800 Iberville 

St., New Orleans, LA 70112. 

Contact Person: Abby Sandler, PhD, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 

Building 6116, Room 212, 6116 Executive 

Boulevard, Bethesda, MD 20892, 301–451–

9399. 

Any interested person may file written 

comments with the committee by forwarding 

the comments to the Contact Person listed on 

this notice. The comments should include 

the name, address, telephone number and, 

when applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

deainfo.nci.nih.gov/advisory/pcp/pcp.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: December 19, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–6186 Filed 12–27–07; 8:45 am] 

BILLING CODE 4140–01–M 

mstockstill on PROD1PC66 with NOTICES